一品红：子公司获得盐酸右美托咪定注射液注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration of Dexmedetomidine Hydrochloride Injection, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Dexmedetomidine Hydrochloride Injection [1] - The main ingredient of the drug is Dexmedetomidine Hydrochloride, and it is formulated as an injection with a specification of 2ml:0.2mg (calculated as C13H16N2) [1] - The registration classification for this drug is categorized as Class 3 chemical drugs [1]